Izotropic Corporation Integrates Radiation Dose Personalization Technology into Breast CT System
TL;DR
Izotropic's radiation dose personalization feature positions its IzoView system as the first breast CT with customized dosing, offering a competitive edge in the $8.69 billion global breast imaging market.
The system uses a radiation-free optical pre-scan and proprietary software to calculate personalized dosing based on each patient's breast size, streamlining exam setup and improving comfort.
This innovation makes breast cancer imaging safer and more comfortable for patients while advancing early detection capabilities to improve healthcare outcomes worldwide.
Izotropic developed the first breast CT system with real-time personalized dosing using models from UC Davis Medical Center, now advancing through FDA approval for U.S. and European markets.
Found this article helpful?
Share it with your network and spread the knowledge!
Izotropic Corporation has announced the integration of a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, marking a substantial advancement in breast cancer imaging technology. The innovation utilizes a radiation-free optical pre-scan combined with proprietary software to calculate customized dosing specific to each patient's breast size, addressing a critical need for personalized medical imaging approaches.
The new technology streamlines examination setup while simultaneously improving patient comfort during breast imaging procedures. Developed using models from UC Davis Medical Center, this system positions IzoView as the first breast CT technology capable of offering real-time personalized dosing. This development comes at a time when the global breast imaging market is projected to grow to $8.69 billion by 2030, indicating significant market potential for advanced imaging solutions.
Izotropic is currently advancing the IzoView system through the FDA Pre-Market Approval process and preparing for pivotal clinical trials in the United States. These trials will support the company's commercialization strategy targeting both U.S. and European markets. The integration of personalized dosing technology represents a meaningful step forward in radiation safety protocols within breast imaging, potentially setting new standards for patient care in mammography and breast CT procedures.
For investors and stakeholders following the company's progress, additional information is available through the company's newsroom. The technology's development using UC Davis Medical Center models provides scientific credibility to the innovation, while the patent-pending status underscores the proprietary nature of this advancement in medical imaging.
The implications of this technological integration extend beyond immediate clinical benefits. By personalizing radiation exposure based on individual patient anatomy, Izotropic addresses growing concerns about cumulative radiation exposure in medical imaging. This approach aligns with broader industry trends toward precision medicine and patient-specific treatment protocols. The timing of this announcement coincides with increasing regulatory focus on radiation safety in medical imaging, potentially giving Izotropic a competitive advantage in regulatory approval processes.
As breast cancer remains one of the most commonly diagnosed cancers worldwide, advancements in imaging technology that improve both diagnostic accuracy and patient safety have significant public health implications. The IzoView system's ability to provide personalized dosing while maintaining imaging quality could influence future standards in breast cancer screening and diagnosis protocols across healthcare systems globally.
Curated from InvestorBrandNetwork (IBN)
